Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.

Vaccine
Jeffry ShearerVladimir Savransky

Abstract

The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for post-exposure prophylaxis (PEP) against inhalational anthrax. In clinical studies, two vaccinations with AV7909 administered either two or four weeks apart induced an enhanced immune response compared to BioThrax® (Anthrax Vaccine Adsorbed) (AVA). Anthrax toxin-neutralizing antibody (TNA) levels on Day 70 following initial vaccination that were associated with protection of animals exposed to inhalational anthrax were previously reported for the 0, 4-week AV7909 vaccination regimen. The current study shows that a 0, 2-week AV7909 vaccination regimen protected guinea pigs (GPs) and nonhuman primates (NHPs) against a lethal inhalational anthrax challenge on Days 28 and 70 after the first immunization. An earlier induction of protective TNA levels using a 0, 2-week AV7909 vaccination regimen may provide benefit over the currently approved AVA PEP 0, 2, and 4-week vaccination regimen.

References

Jan 1, 1985·Journal of Toxicology and Environmental Health·R B Schlesinger
Jan 5, 2002·Antisense & Nucleic Acid Drug Development·R RankinS van Drunen Littel-van den Hurk
Aug 16, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Daphne VasconcelosJohn Carney
Mar 1, 1956·The Journal of Hygiene·D W HENDERSONF C BELTON
Jul 1, 1947·The American Journal of Physiology·A C GUYTON
Jun 20, 2012·Current Opinion in Virology·Drusilla L Burns
Sep 14, 2012·Science Translational Medicine·Michael P FayEdwin O Nuzum
Jan 30, 2013·Infection and Immunity·Vladimir SavranskyMario H Skiadopoulos
May 10, 2013·Clinical and Vaccine Immunology : CVI·Boris IoninMario H Skiadopoulos
Dec 14, 2019·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·William A BowerUNKNOWN ACIP Anthrax Vaccine Work Group

❮ Previous
Next ❯

Citations

Jul 21, 2021·International Journal of Toxicology·Veena V RaoVladimir Savransky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.